PASS to End TB in Europe: Accelerated efforts on prevention and systematic screening to end tuberculosis in the WHO European Region by 2030.

Eastern Europe MDR-TB Prevention Systematic screening TB Technical assistance

Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Apr 2024
Historique:
received: 17 01 2024
revised: 14 02 2024
accepted: 15 02 2024
medline: 15 4 2024
pubmed: 26 2 2024
entrez: 25 2 2024
Statut: ppublish

Résumé

Outline the objectives, methods, and initial stages of the Prevention and Systematic Screening (PASS) initiative, a complimentary element of the innovative new approach of technical assistance mechanisms of WHO and its partners to countries aligned to the Regional TB Action Plan to End TB in the European Region by 2030. To provide an objective and critical overview of the existing landscape on TB epidemic in the WHO European Region (the European Region) and ii) identify the strategic significance of proactive measures aimed at approaching TB pre-elimination in the Region. Interventions primarily include systematic screening for TB disease and treatment for TB infection (TBI). PASS to End TB is an exemplary initiative of how technical and funding partners are joining hands to support national health programmes to work towards global commitments to curb major public health challenges like TB.

Identifiants

pubmed: 38403111
pii: S1201-9712(24)00051-1
doi: 10.1016/j.ijid.2024.02.023
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106980

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Andrei Dadu (A)

World Health Organization, Regional Office for Europe, European Tuberculosis Programme, Copenhagen, Denmark.

Askar Yedilbayev (A)

World Health Organization, Regional Office for Europe, European Tuberculosis Programme, Copenhagen, Denmark.

Giovanni Battista Migliori (GB)

Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy. Electronic address: giovannibattista.migliori@icsmaugeri.it.

Sevim Ahmedov (S)

The United States Agency of International Development (USAID), Bureau of Global Health, TB Division, Washington, DC, USA.

Dennis Falzon (D)

World Health Organization, Global Tuberculosis Programme, Geneva, Switzerland.

Saskia den Boon (S)

World Health Organization, Global Tuberculosis Programme, Geneva, Switzerland.

Avinash Kanchar (A)

World Health Organization, Global Tuberculosis Programme, Geneva, Switzerland.

Alberto Matteelli (A)

Department of Clinical and Experimental Sciences (DSCS), WHO Collaborating Centre on Tuberculosis Prevention, Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH